Oncologic Drugs Advisory Committee

Company

Related News

Alliance, Allarity Launch Lung Cancer Trials as Phase I Sites Consolidate

Jun 25, 2026

Alliance launches Phase III trial for stage I NSCLC immunotherapy; Allarity starts Phase 2 SCLC trial. Phase I NSCLC trial sites consolidate at top U.S. sites, prompting FDA representation concerns.

FDA Panel Votes Against AstraZeneca's Breast Cancer Drug Camizestrant

May 01, 2026

FDA's ODAC voted 6-3 against AstraZeneca's camizestrant for HR+/HER2- metastatic breast cancer, citing uncertain clinical benefit from the SERENA-6 trial design. The FDA raised concerns about the early-switch treatment paradigm and long-term outcomes.